Rexahn Pharmaceuticals has entered into a collaboration and license agreement with Zhejiang Haichang Biotechnology (Haichang), to develop RX-0201 (Archexin) for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.   Under the terms of the agreement, Haichang will develop a nano-liposomal formulation of RX-0201 using its QTsome technology and conduct certain pre-clinical and clinical activities through completion of a Phase IIa proof-of-concept clinical t...